#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics to Showcase Innovations at Investor Conferences

Sera Prognostics Inc., known as The Pregnancy Company®, is set to participate in multiple investor conferences aimed at fostering dialogue about maternal and neonatal health innovations. The company is recognized for its commitment to improving pregnancy outcomes through advanced diagnostic solutions. The upcoming conferences include the William Blair 45th Annual Growth Stock Conference and the Jefferies Global Healthcare Conference, both taking place from June 3 to 5, 2025.

During these events, Sera Prognostics aims to present insights into its innovative approaches to identifying pregnancy complications. Members of the Sera team will engage with investors to discuss the significance of their cutting-edge tests, particularly the PreTRM® Test, which offers personalized risk assessment for spontaneous preterm birth.

Focus on Investor Engagement

At the William Blair conference, Doug Fisher, M.D., a strategic advisor to Sera and former Chief Business Officer, will hold one-on-one meetings with investors on June 4, 2025. These meetings are designed to provide tailored insights into Sera's operations and future direction.

The Jefferies Global Healthcare Conference will feature a notable presentation from Zhenya Lindgardt, President and CEO, who is scheduled to deliver a company update on June 4 from 3:10 to 3:40 p.m. ET. Accompanying him will be CFO Austin Aerts, who will also participate in meetings during the conference. Their discussions are expected to highlight recent achievements and ongoing initiatives aimed at enhancing maternal and neonatal health.

Commitment to Maternal Health

Sera Prognostics is based in Salt Lake City, Utah, and is dedicated to improving health outcomes for mothers and their newborns. The company's flagship PreTRM® Test provides valuable biomarkers that assess the risk of preterm birth as early as 18 to 20 weeks in gestation. This vital information enables healthcare providers to make informed clinical decisions and undertake proactive measures for at-risk pregnancies.

With preterm birth being a leading cause of health complications among newborns, the significance of Sera's work cannot be overstated. The March of Dimes Report Card indicated that more than one in ten infants in the U.S. is born prematurely, which correlates with numerous long-term health issues. By providing healthcare professionals with precise data about preterm birth risk, Sera aims to mitigate these concerning trends.

The Importance of the PreTRM® Test

The PreTRM® Test is the only commercially available blood-based biomarker test for predicting preterm birth. It measures specific proteins in the blood that correlate strongly with the likelihood of early delivery, thus allowing doctors to tailor care based on individual risk levels. This personalized approach represents a shift towards precision medicine in pregnancy care, aiming to improve outcomes for mothers and their children alike.

Conclusion

As Sera Prognostics prepares to take part in these significant investor conferences, the company reaffirms its commitment to advancing maternal health through innovative diagnostic solutions. By fostering connections with investors and sharing the latest advancements in their research, Sera looks to secure support for its mission. The results of these efforts could lead to substantial improvements in maternity care and solidify Sera's position as a leader in the field.

For live updates and more information about Sera Prognostics and their participation at the conferences, you can visit their official site at www.sera.com.